Burgundy Asset Management Ltd. Has $151.05 Million Position in Henry Schein, Inc. $HSIC

Burgundy Asset Management Ltd. lessened its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 1.7% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 2,170,871 shares of the company’s stock after selling 36,622 shares during the quarter. Henry Schein comprises about 1.4% of Burgundy Asset Management Ltd.’s investment portfolio, making the stock its 29th biggest position. Burgundy Asset Management Ltd.’s holdings in Henry Schein were worth $151,049,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. CYBER HORNET ETFs LLC bought a new position in Henry Schein in the 2nd quarter valued at about $25,000. MUFG Securities EMEA plc acquired a new position in shares of Henry Schein in the second quarter valued at approximately $27,000. Sentry Investment Management LLC increased its stake in shares of Henry Schein by 132.1% during the third quarter. Sentry Investment Management LLC now owns 905 shares of the company’s stock worth $59,000 after purchasing an additional 515 shares during the period. Evelyn Partners Investment Management Services Ltd acquired a new stake in Henry Schein during the 2nd quarter worth approximately $62,000. Finally, Mather Group LLC. bought a new stake in Henry Schein in the 3rd quarter valued at $71,000. Institutional investors own 96.62% of the company’s stock.

Insider Activity

In other news, CEO Stanley M. Bergman sold 43,812 shares of Henry Schein stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $81.31, for a total transaction of $3,562,353.72. Following the transaction, the chief executive officer owned 383,803 shares in the company, valued at approximately $31,207,021.93. The trade was a 10.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 92,943 shares of company stock worth $7,544,505 over the last ninety days. 1.08% of the stock is currently owned by company insiders.

Henry Schein Trading Up 0.5%

HSIC opened at $80.58 on Thursday. The company’s 50 day moving average is $78.09 and its 200-day moving average is $72.44. The company has a market cap of $9.24 billion, a P/E ratio of 24.64, a PEG ratio of 2.37 and a beta of 0.88. Henry Schein, Inc. has a 1-year low of $60.56 and a 1-year high of $89.29. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same period in the prior year, the company earned $1.19 EPS. Henry Schein’s revenue was up 7.7% compared to the same quarter last year. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities research analysts predict that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Analyst Ratings Changes

HSIC has been the topic of several recent research reports. Mizuho increased their price objective on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 25th. UBS Group upped their price target on shares of Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a research note on Wednesday, February 25th. Evercore lifted their price objective on shares of Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 5th. Robert W. Baird set a $100.00 price objective on shares of Henry Schein and gave the company an “outperform” rating in a report on Monday, February 23rd. Finally, Leerink Partners increased their target price on shares of Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a research report on Tuesday, February 24th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $85.58.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.